DOCSLIB.ORG

Etats Rapides

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Etats Rapides List of European Pharmacopoeia Reference Standards Effective from 2016/1/6 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit Y0001756 Exemestane for system suitability 1 10 mg 1 2766 Yes +5°C ± 3°C 79 € Y0001561 Abacavir sulfate 1 20 mg 1 2589 Yes +5°C ± 3°C 79 € Y0001552 Abacavir for peak identification 1 10 mg 1 2589 Yes +5°C ± 3°C 79 € Y0001551 Abacavir for system suitability 1 10 mg 1 2589 Yes +5°C ± 3°C 79 € Y0000055 Acamprosate calcium - reference spectrum 1 n/a 1 1585 79 € Y0000116 Acamprosate impurity A 1 50 mg 1 3-aminopropane-1-sulphonic acid 1585 Yes +5°C ± 3°C 79 € Y0000500 Acarbose 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 August 2015 2089 Yes +5°C ± 3°C 79 € Y0000354 Acarbose for identification 1 10 mg 1 2089 Yes +5°C ± 3°C 79 € Y0000427 Acarbose for peak identification 3 20 mg 1 Batch 2 is valid until 31 January 2015 2089 Yes +5°C ± 3°C 79 € A0040000 Acebutolol hydrochloride 1 50 mg 1 0871 Yes +5°C ± 3°C 79 € Y0000359 Acebutolol impurity B 2 10 mg 1 -[3-acetyl-4-[(2RS)-2-hydroxy-3-[(1-methylethyl)amino] propoxy]phenyl] 0871 Yes +5°C ± 3°C 79 € acetamide (diacetolol) Y0000127 Acebutolol impurity C 1 20 mg 1 N-(3-acetyl-4-hydroxyphenyl)butanamide 0871 Yes +5°C ± 3°C 79 € Y0000128 Acebutolol impurity I 2 0.004 mg 1 N-[3-acetyl-4-[(2RS)-3-(ethylamino)-2-hydroxypropoxy]phenyl] 0871 Yes +5°C ± 3°C 79 € butanamide Y0000056 Aceclofenac - reference spectrum 1 n/a 1 1281 79 € Y0000085 Aceclofenac impurity F 2 15 mg 1 benzyl[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetate 1281 Yes +5°C ± 3°C 79 € Y0000086 Aceclofenac impurity H 1 10 mg 1 [[[[[[[2-[(2,6-dichlorophenyl)amino]phenyl]acetyl]oxy]acetyl] oxy]acetyl]oxy] 1281 Yes +5°C ± 3°C 79 € acetic acid Y0001094 Aceclofenac for peak identification 1 10 mg 1 1281 Yes +5°C ± 3°C 79 € Y0000810 Acemetacin 1 100 mg 1 1686 Yes +5°C ± 3°C 79 € Y0000811 Acemetacin impurity A 1 10 mg 1 4-chlorobenzoic acid 1686 Yes +5°C ± 3°C 79 € Y0000842 Acemetacin impurity mixture 1 0.06 mg 1 1686 Yes +5°C ± 3°C 79 € A0070000 Acesulfame potassium 2 50 mg 1 1282 Yes +5°C ± 3°C 79 € A0070020 Acesulfame potassium impurity B 4 15 mg 1 see leaflet; 5-chloro-6-methyl-1,2,3-oxathiazin-4(3§)-one 2,2-dioxide 1282 Yes +5°C ± 3°C 79 € A0100000 Acetazolamide 1 100 mg 1 0454 Yes +5°C ± 3°C 79 € Y0001084 Acetazolamide for system suitability 2 0.0068 mg 1 Batch 1 is valid until 31 May 2015 0454 Yes +5°C ± 3°C 79 € Y0000002 Acetylcholine chloride 1 50 mg 1 1485,1971 Yes -20°C ± 5°C 79 € A0150000 Acetylcysteine 3 50 mg 1 0967 Yes +5°C ± 3°C 79 € A0152000 Acetylcysteine impurity C 9 10 mg 1 See leaflet; N,N'-diacetyl-L-cystine 0967 Yes +5°C ± 3°C 79 € A0153000 Acetylcysteine impurity D 6 10 mg 1 N,£-diacetyl-L-cysteine ; Batch 5 is valid until 28 May 2015 0967 Yes +5°C ± 3°C 79 € Y0000565 ß-Acetyldigoxin 2 50 mg 1 See leaflet C÷–HÿÿOŒ— 2168 Yes +5°C ± 3°C 79 € Y0000642 ß-Acetyldigoxin for peak identification 1 10 mg 1 2168 Yes +5°C ± 3°C 79 € A0200000 Acetylsalicylic acid 4 15 mg 1 0309 Yes +5°C ± 3°C 79 € Y0001460 Acetylsalicylic acid for peak identification 2 10.3 mg 1 0309 Yes +5°C ± 3°C 79 € Y0001462 Acetylsulfadiazine 1 0.002 mg 1 0294 Yes +5°C ± 3°C 79 € A0208000 N-Acetyltryptophan 2 125 mg 1 1383 Yes +5°C ± 3°C 79 € © Council of Europe, all rights reserved 2016 1 For extra charges, please see supply terms and conditions. List of European Pharmacopoeia Reference Standards Effective from 2016/1/6 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit A0202000 N-Acetyltyrosine 1 200 mg 1 1384 Yes +5°C ± 3°C 79 € Y0000693 Acholeplasma laidlawii BRP 1 1 ml 1 20607 Yes -80°C ± 10°C 120 € A0220000 Aciclovir 3 75 mg 1 0968 Yes +5°C ± 3°C 79 € Y0001271 Aciclovir for peak identification 1 3 0.303 mg 1 0968 Yes +5°C ± 3°C 79 € Y0001269 Aciclovir for peak identification 2 3 0.004 mg 1 0968 Yes +5°C ± 3°C 79 € Y0001264 Aciclovir for system suitability 1 10 mg 1 0968 Yes +5°C ± 3°C 79 € A0225000 Acitretin 2 100 mg 1 See leaflet CœŒHœÿO– 1385 Yes +5°C ± 3°C 79 € Y0001463 Actaea racemosa HRS 1 1200 mg 1 2069 Yes +5°C ± 3°C 79 € Y0001543 Actaea racemosa for assay CRS 1 300 mg 1 See leaflet C÷œHÿ—NOŒÿ; Monoammonium glycyrrhizate 2069 Yes +5°C ± 3°C 79 € Y0001464 Actaea racemosa dry extract for system suitability HRS 1 1200 mg 1 2069 Yes -20°C ± 5°C 79 € Y0001121 Adapalene 1 100 mg 1 See leaflet Cœ‡Hœ‡O– 2445 Yes +5°C ± 3°C 79 € Y0001120 Adapalene impurity C 3 6 mg 1 1-[2-(methyloxy)phenyl]tricyclo[3.3.1.1]decane 2445 Yes +5°C ± 3°C 79 € Y0001119 Adapalene for peak identification 2 2.022 mg 1 Batch 1 is valid until 31 March 2016 2445 Yes +5°C ± 3°C 79 € A0230000 Adenine 2 50 mg 1 0800 Yes +5°C ± 3°C 79 € A0230200 Adenosine 1 50 mg 1 1486 Yes +5°C ± 3°C 79 € Y0000110 Adipic acid 1 50 mg 1 1586 Yes +5°C ± 3°C 79 € Y0000882 Adrenaline 1 5 mg 1 2303 Yes +5°C ± 3°C 79 € Y0000740 Adrenaline impurity mixture 3 0.0045 mg 1 0254,2303 Yes +5°C ± 3°C 79 € Y0000883 Adrenaline with impurity F 1 10 mg 1 2303 Yes +5°C ± 3°C 79 € A0300000 Adrenaline tartrate 5 100 mg 1 0254 Yes +5°C ± 3°C 79 € Y0000707 Adrenaline tartrate with impurity A 1 15 mg 1 0254 Yes +5°C ± 3°C 79 € Y0001724 Agnus castus fruit dry extract 1 350 mg 1 see leaflet 2309, 2147 Yes -20°C ± 5°C 79 € A0325000 Alanine 3 60 mg 1 0752 Yes +5°C ± 3°C 79 € A0325100 Albendazole 2 50 mg 1 Batch 1 is valid until 31 December 2015 1386 Yes +5°C ± 3°C 79 € A0325200 Alcuronium chloride 2 50 mg 1 1285 Yes -20°C ± 5°C 79 € A0325450 Alfacalcidol 9 5 mg 1 See leaflet ; Batch 8 is valid until 31 October 2015 1286 Yes -20°C ± 5°C 300 € Y0001601 Alfacalcidol for system suitability 1 2.5 mg 1 1286 Yes -20°C ± 5°C 79 € A0325451 Alfacalcidol - reference spectrum 1 n/a 1 1286 79 € A1225000 Alfadex 3 150 mg 1 See leaflet [CÿHŒÐ0—]ÿ 1070,1487 Yes +5°C ± 3°C 79 € A0325500 Alfentanil hydrochloride - reference spectrum 1 n/a 1 1062 79 € A0325800 Alfuzosin hydrochloride 2 10 mg 1 1287 Yes +5°C ± 3°C 79 € Y0000832 Alfuzosin for system suitability 1 10 mg 1 1287 Yes +5°C ± 3°C 79 € Y0001583 Alimemazine hemitartrate 1 15 mg 1 2650 Yes +5°C ± 3°C 79 € Y0001581 Alimemazine for system suitability 1 5 mg 1 2650 Yes +5°C ± 3°C 79 € A0349000 Allantoin 1 60 mg 1 1288 Yes +5°C ± 3°C 79 € A0350000 Allopurinol 3 100 mg 1 See leaflet ; Batch 2 is valid until 31 October 2015 0576 Yes +5°C ± 3°C 79 € © Council of Europe, all rights reserved 2016 2 For extra charges, please see supply terms and conditions. List of European Pharmacopoeia Reference Standards Effective from 2016/1/6 Order Reference Standard Batch n° Quantity Sale Information Monograph Leaflet Storage Price Code per vial Unit A0350010 Allopurinol impurity A 2 10 mg 1 5-amino-1H-pyrazole-4-carboxamide 0576 Yes +5°C ± 3°C 79 € A0350020 Allopurinol impurity B 3 10 mg 1 5-formylamino-1H-pyrazole-4-carboxamide 0576 Yes +5°C ± 3°C 79 € A0350030 Allopurinol impurity C 3 10 mg 1 5-(4H-1,2,4-triazol-4-yl)-1H-pyrazole-4-carboxamide 0576 Yes +5°C ± 3°C 79 € A0350040 Allopurinol impurity D 4 15 mg 1 ethyl 5-amino-1H-pyrazole-4-carboxylate ; Batch 3 is valid until 30 September 0576 Yes +5°C ± 3°C 79 € 2015 A0350050 Allopurinol impurity E 1 20 mg 1 ethyl 5-(formylamino)-1H-pyrazole-4-carboxylate 0576 Yes +5°C ± 3°C 79 € A0351000 Allylstrychnine bromide 1 10 mg 1 1285 Yes -20°C ± 5°C 79 € Y0000235 Almagate 1 25 mg 1 See leaflet 2010 Yes +5°C ± 3°C 79 € Y0000255 Almagate - reference spectrum 1 n/a 1 2010 79 € A0357000 Alprazolam - * psy 2 100 mg 1 1065 Yes +5°C ± 3°C 79 € A0360000 Alprenolol hydrochloride 1 100 mg 1 0628,0876 Yes +5°C ± 3°C 79 € Y0000054 Alprostadil 2 50 mg 1 see leaflet 1488 Yes -20°C ± 5°C 79 € Y0000606 Altizide 2 150 mg 1 See leaflet CŒŒHŒ÷ClN–O÷S– 0370,2185 Yes +5°C ± 3°C 79 € Y0000843 Altizide impurity B 1 15 mg 1 3-[(2,2-dimethoxyethyl)sulphanyl]prop-1-ene 2185 Yes +5°C ± 3°C 79 € Y0000687 Alverine citrate 1 5 mg 1 2156 Yes +5°C ± 3°C 79 € Y0000607 Alverine impurity D 1 10 mg 1 N-(3-cyclohexylpropyl)-N-ethyl-3-phenylpropan-1-amine 2156 Yes +5°C ± 3°C 79 € Y0000595 Alverine for peak identification 2 0.125 mg 1 2156 Yes -20°C ± 5°C 79 € A0363000 Amantadine hydrochloride 1 100 mg 1 0463 Yes +5°C ± 3°C 79 € A0363700 Ambroxol hydrochloride 3 125 mg 1 1489 Yes +5°C ± 3°C 79 € A0900000 Amfetamine sulfate - reference spectrum 1 n/a 1 0368 79 € A0365000 Amidotrizoic acid dihydrate 1 100 mg 1 0873 Yes +5°C ± 3°C 79 € Y0001461 Amidotrizoic acid for system suitability 1 0.08 mg 1 0873 Yes +5°C ± 3°C 79 € A0368000 Amikacin 3 200 mg 1 See leaflet 1289,1290 Yes +5°C ± 3°C 79 € Y0001467 Amikacin impurity I 1 20 mg 1 (2S)-4-amino-2-hydroxybutanoic acid 1289, 1290 Yes +5°C ± 3°C 79 € New Y0001117 Amikacin for system suitability 3 10 mg 1 Batch 2 is valid until 30 June 2016 1289,1290 Yes +5°C ± 3°C 79 € A0365900 Amikacin sulfate 3 200 mg 1 The batch 3 is not suitable for use in the assay in monograph 1290:07/2014.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 Mckay Et Al
    US 20080317805A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2008/0317805 A1 McKay et al. (43) Pub. Date: Dec. 25, 2008 (54) LOCALLY ADMINISTRATED LOW DOSES Publication Classification OF CORTICOSTEROIDS (51) Int. Cl. A6II 3/566 (2006.01) (76) Inventors: William F. McKay, Memphis, TN A6II 3/56 (2006.01) (US); John Myers Zanella, A6IR 9/00 (2006.01) Cordova, TN (US); Christopher M. A6IP 25/04 (2006.01) Hobot, Tonka Bay, MN (US) (52) U.S. Cl. .......... 424/422:514/169; 514/179; 514/180 (57) ABSTRACT Correspondence Address: This invention provides for using a locally delivered low dose Medtronic Spinal and Biologics of a corticosteroid to treat pain caused by any inflammatory Attn: Noreen Johnson - IP Legal Department disease including sciatica, herniated disc, Stenosis, mylopa 2600 Sofamor Danek Drive thy, low back pain, facet pain, osteoarthritis, rheumatoid Memphis, TN38132 (US) arthritis, osteolysis, tendonitis, carpal tunnel syndrome, or tarsal tunnel syndrome. More specifically, a locally delivered low dose of a corticosteroid can be released into the epidural (21) Appl. No.: 11/765,040 space, perineural space, or the foramenal space at or near the site of a patient's pain by a drug pump or a biodegradable drug (22) Filed: Jun. 19, 2007 depot. E Day 7 8 Day 14 El Day 21 3OO 2OO OO OO Control Dexamethasone DexamethasOne Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr 0.0032ng/hr 0.016 ng/hr 0.08 ng/hr Patent Application Publication Dec. 25, 2008 Sheet 1 of 2 US 2008/0317805 A1 900 ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- 80.0 - 7OO – 6OO - 5OO - E Day 7 EDay 14 40.0 - : El Day 21 2OO - OO = OO – Dexamethasone Dexamethasone Dexamethasone Fuocinolone Fluocinolone Fuocinolone 2.0 ng/hr 1Ong/hr 50 ng/hr O.OO32ng/hr O.016 ng/hr 0.08 nghr Patent Application Publication Dec.
    [Show full text]
  • A Comparison of Fluticasone Propionate, 1 Mg Daily, with Beclomethasone Dipropionate, 2 Mg Daily, in the Treatment of Severe Asthma
    Copyright ©ERS Joumals Ltd 1993 Eur Respir J , 1993, 6, Sn-884 European Respiratory Joumal Printed in UK - all rights reserved ISSN 0903 - 1936 A comparison of fluticasone propionate, 1 mg daily, with beclomethasone dipropionate, 2 mg daily, in the treatment of severe asthma N.C. Bames*, G. Marone**, G.U. Di Maria***, S. Visser, I. Utama++, S.L. Payne+++, on behalf of an International Study Group A comparison of fluticasone propionate. 1 mg daily, with beclomethasone dipropionate, • The London Chest Hospital, London, 2 mg daily, in the treatment of severe asthma. N. C. Bames, G. Marone, G.U. Di Maria, UK. ** Servizio di Allergologia e S. Visser. l Utama, S.L Payne, on behalf of an International Study Group. @ERS Immunologia Clinica. I Clinica Medica Journals Ltd 1993. Universita, Napoli, Italy. *** lnstituto Malattie Respiratorie, Ospedale Tomaselli, ABSTRACT: We wanted w compare the efficacy and safety of fluticasone propi­ Catania, Sicily, Italy. onate, a new topically active inhaled corticosteroid, to that of high dose beclo­ + H.F. Verwoerd Hospital, Pretoria, South methasone dipropionate, in severe adult asthma. Africa. ++ St Laurentius Ziekenhius, 1 Patients currently receiving between 1.5-2.0 mg·day- of an inhaled corticoster­ CV Roermond, The Netherlands. +++ oid were treated for six weeks in a double-blind, randomized, parallel group study Glaxo Group Research Ltd, Greenford, with 1 mg·day-1 fluticasone propionate (n•82), or 2 mg·day·1 beclometbasone Middlesex, UK. dipropionate (n•72). Mean morning peak expirarory flow rates (PEFR) increased from 303 w 321 Correspondence: N.C. Bames l·min-1 with fluticasone propionate, and from 294 w 319 l·min·1 with beclometbasone The London Chest Hospital dipropionate.
    [Show full text]
  • This Fact Sheet Provides Information to Patients with Eczema and Their Carers. About Topical Corticosteroids How to Apply Topic
    This fact sheet provides information to patients with eczema and their carers. About topical corticosteroids You or your child’s doctor has prescribed a topical corticosteroid for the treatment of eczema. For treating eczema, corticosteroids are usually prepared in a cream or ointment and are applied topically (directly onto the skin). Topical corticosteroids work by reducing inflammation and helping to control an over-reactive response of the immune system at the site of eczema. They also tighten blood vessels, making less blood flow to the surface of the skin. Together, these effects help to manage the symptoms of eczema. There is a range of steroids that can be used to treat eczema, each with different strengths (potencies). On the next page, the potencies of some common steroids are shown, as well as the concentration that they are usually used in cream or ointment preparations. Using a moisturiser along with a steroid cream does not reduce the effect of the steroid. There are many misconceptions about the side effects of topical corticosteroids. However these treatments are very safe and patients are encouraged to follow the treatment regimen as advised by their doctor. How to apply topical corticosteroids How often should I apply? How much should I apply? Apply 1–2 times each day to the affected area Enough cream should be used so that the of skin according to your doctor’s instructions. entire affected area is covered. The cream can then be rubbed or massaged into the Once the steroid cream has been applied, inflamed skin. moisturisers can be used straight away if needed.
    [Show full text]
  • The National Drugs List
    ^ ^ ^ ^ ^[ ^ The National Drugs List Of Syrian Arab Republic Sexth Edition 2006 ! " # "$ % &'() " # * +$, -. / & 0 /+12 3 4" 5 "$ . "$ 67"5,) 0 " /! !2 4? @ % 88 9 3: " # "$ ;+<=2 – G# H H2 I) – 6( – 65 : A B C "5 : , D )* . J!* HK"3 H"$ T ) 4 B K<) +$ LMA N O 3 4P<B &Q / RS ) H< C4VH /430 / 1988 V W* < C A GQ ") 4V / 1000 / C4VH /820 / 2001 V XX K<# C ,V /500 / 1992 V "!X V /946 / 2004 V Z < C V /914 / 2003 V ) < ] +$, [2 / ,) @# @ S%Q2 J"= [ &<\ @ +$ LMA 1 O \ . S X '( ^ & M_ `AB @ &' 3 4" + @ V= 4 )\ " : N " # "$ 6 ) G" 3Q + a C G /<"B d3: C K7 e , fM 4 Q b"$ " < $\ c"7: 5) G . HHH3Q J # Hg ' V"h 6< G* H5 !" # $%" & $' ,* ( )* + 2 ا اوا ادو +% 5 j 2 i1 6 B J' 6<X " 6"[ i2 "$ "< * i3 10 6 i4 11 6! ^ i5 13 6<X "!# * i6 15 7 G!, 6 - k 24"$d dl ?K V *4V h 63[46 ' i8 19 Adl 20 "( 2 i9 20 G Q) 6 i10 20 a 6 m[, 6 i11 21 ?K V $n i12 21 "% * i13 23 b+ 6 i14 23 oe C * i15 24 !, 2 6\ i16 25 C V pq * i17 26 ( S 6) 1, ++ &"r i19 3 +% 27 G 6 ""% i19 28 ^ Ks 2 i20 31 % Ks 2 i21 32 s * i22 35 " " * i23 37 "$ * i24 38 6" i25 39 V t h Gu* v!* 2 i26 39 ( 2 i27 40 B w< Ks 2 i28 40 d C &"r i29 42 "' 6 i30 42 " * i31 42 ":< * i32 5 ./ 0" -33 4 : ANAESTHETICS $ 1 2 -1 :GENERAL ANAESTHETICS AND OXYGEN 4 $1 2 2- ATRACURIUM BESYLATE DROPERIDOL ETHER FENTANYL HALOTHANE ISOFLURANE KETAMINE HCL NITROUS OXIDE OXYGEN PROPOFOL REMIFENTANIL SEVOFLURANE SUFENTANIL THIOPENTAL :LOCAL ANAESTHETICS !67$1 2 -5 AMYLEINE HCL=AMYLOCAINE ARTICAINE BENZOCAINE BUPIVACAINE CINCHOCAINE LIDOCAINE MEPIVACAINE OXETHAZAINE PRAMOXINE PRILOCAINE PREOPERATIVE MEDICATION & SEDATION FOR 9*: ;< " 2 -8 : : SHORT -TERM PROCEDURES ATROPINE DIAZEPAM INJ.
    [Show full text]
  • (CD-P-PH/PHO) Report Classification/Justifica
    COMMITTEE OF EXPERTS ON THE CLASSIFICATION OF MEDICINES AS REGARDS THEIR SUPPLY (CD-P-PH/PHO) Report classification/justification of medicines belonging to the ATC group D07A (Corticosteroids, Plain) Table of Contents Page INTRODUCTION 4 DISCLAIMER 6 GLOSSARY OF TERMS USED IN THIS DOCUMENT 7 ACTIVE SUBSTANCES Methylprednisolone (ATC: D07AA01) 8 Hydrocortisone (ATC: D07AA02) 9 Prednisolone (ATC: D07AA03) 11 Clobetasone (ATC: D07AB01) 13 Hydrocortisone butyrate (ATC: D07AB02) 16 Flumetasone (ATC: D07AB03) 18 Fluocortin (ATC: D07AB04) 21 Fluperolone (ATC: D07AB05) 22 Fluorometholone (ATC: D07AB06) 23 Fluprednidene (ATC: D07AB07) 24 Desonide (ATC: D07AB08) 25 Triamcinolone (ATC: D07AB09) 27 Alclometasone (ATC: D07AB10) 29 Hydrocortisone buteprate (ATC: D07AB11) 31 Dexamethasone (ATC: D07AB19) 32 Clocortolone (ATC: D07AB21) 34 Combinations of Corticosteroids (ATC: D07AB30) 35 Betamethasone (ATC: D07AC01) 36 Fluclorolone (ATC: D07AC02) 39 Desoximetasone (ATC: D07AC03) 40 Fluocinolone Acetonide (ATC: D07AC04) 43 Fluocortolone (ATC: D07AC05) 46 2 Diflucortolone (ATC: D07AC06) 47 Fludroxycortide (ATC: D07AC07) 50 Fluocinonide (ATC: D07AC08) 51 Budesonide (ATC: D07AC09) 54 Diflorasone (ATC: D07AC10) 55 Amcinonide (ATC: D07AC11) 56 Halometasone (ATC: D07AC12) 57 Mometasone (ATC: D07AC13) 58 Methylprednisolone Aceponate (ATC: D07AC14) 62 Beclometasone (ATC: D07AC15) 65 Hydrocortisone Aceponate (ATC: D07AC16) 68 Fluticasone (ATC: D07AC17) 69 Prednicarbate (ATC: D07AC18) 73 Difluprednate (ATC: D07AC19) 76 Ulobetasol (ATC: D07AC21) 77 Clobetasol (ATC: D07AD01) 78 Halcinonide (ATC: D07AD02) 81 LIST OF AUTHORS 82 3 INTRODUCTION The availability of medicines with or without a medical prescription has implications on patient safety, accessibility of medicines to patients and responsible management of healthcare expenditure. The decision on prescription status and related supply conditions is a core competency of national health authorities.
    [Show full text]
  • Steroids Topical
    Steroids, Topical Therapeutic Class Review (TCR) September 18, 2020 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. September
    [Show full text]
  • Report Name:Ukraine's Mrls for Veterinary Drugs
    Voluntary Report – Voluntary - Public Distribution Date: November 05,2020 Report Number: UP2020-0051 Report Name: Ukraine's MRLs for Veterinary Drugs Country: Ukraine Post: Kyiv Report Category: FAIRS Subject Report Prepared By: Oleksandr Tarassevych Approved By: Robin Gray Report Highlights: Ukraine adopted several maximum residue levels (MRLs) for veterinary drugs, coccidiostats and histomonostats in food products of animal origin. Ukraine also adopted a list of drugs residues that are not allowed in food products. THIS REPORT CONTAINS ASSESSMENTS OF COMMODITY AND TRADE ISSUES MADE BY USDA STAFF AND NOT NECESSARILY STATEMENTS OF OFFICIAL U.S. GOVERNMENT POLICY The Office of Agricultural Affairs of USDA/Foreign Agricultural Service in Kyiv, Ukraine prepared this report for U.S. exporters of domestic food and agricultural products. While every possible care was taken in the preparation of this report, information provided may not be completely accurate either because policies have changed since the time this report was written, or because clear and consistent information about these policies was not available. It is highly recommended U.S. exporters verify the full set of import requirements with their foreign customers, who are normally best equipped to research such matters with local authorities, before any goods are shipped. This FAIRS Subject Report accompanies other reports on Maximum, Residue Limits established by Ukraine in 2020. Related reports could be found under the following links: 1.) Ukraine's MRLs for Microbiological Contaminants_Kyiv_Ukraine_04-27-2020 2.) Ukraine's MRLs for Certain Contaminants_Kyiv_Ukraine_03-06-2020 Food Products of animal origin and/or ingredients of animal origin are not permitted in the Ukrainian market if they contain certain veterinary drugs residues in excess of the maximum residue levels established in Tables 1 and 2.
    [Show full text]
  • Flonase Sensimist Allergy Relief (Fluticasone Furoate)
    Flonase® Sensimist™ Allergy Relief (fluticasone furoate) – Rx-to-OTC Approval • On February 8, 2017, GlaxoSmithKline Consumer Healthcare announced the launch of Flonase Sensimist Allergy Relief (fluticasone furoate) nasal spray, as an over the counter (OTC) treatment to temporarily relieve symptoms of hay fever or other upper respiratory allergies: nasal congestion; runny nose; sneezing; itchy nose; and itchy, watery eyes (in ages 12 years and older). — Flonase Sensimist Allergy Relief contains 27.5 mcg/spray of fluticasone furoate. — Flonase Sensimist Allergy Relief should not be used in children less than 2 years of age. • Previously, fluticasone furoate was only available by prescription as Veramyst®. Veramyst is no longer commercially available. • Fluticasone is also available OTC as brand (Flonase® Allergy Relief, Children’s Flonase® Allergy Relief) and generic products containing 50 mcg/spray of fluticasone propionate. — These products share the same indications as Flonase Sensimist Allergy Relief, but are not intended for children under 4 years of age. • Prescription fluticasone propionate nasal spray (50 mcg/spray) is available generically and indicated for the management of the nasal symptoms of perennial non-allergic rhinitis in adult and pediatric patients aged 4 years and older. • Warnings for Flonase Sensimist Allergy Relief state the following: — Do not use: in children under 2 years of age, to treat asthma, if there is an injury or surgery to the nose that is not fully healed, or if an allergic reaction to Flonase Sensimist Allergy Relief or any of its ingredients has occurred. — Ask a doctor prior to use if the patient has or had glaucoma or cataracts.
    [Show full text]
  • Difference Between Patient-Reported Side Effects of Ciclesonide Versus fluticasone Propionate
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Respiratory Medicine (2010) 104, 1825e1833 available at www.sciencedirect.com journal homepage: www.elsevier.com/locate/rmed Difference between patient-reported side effects of ciclesonide versus fluticasone propionate Thys van der Molen a, Juliet M. Foster a,b, Manfred Caeser c,e, Thomas Mu¨ller c, Dirkje S. Postma d,* a Department of General Practice, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands b Woolcock Institute of Medical Research, 431 Glebe Point Rd, Glebe NSW 2037, Sydney, Australia c Nycomed GmbH, Byk-Gulden-Straße 2, 78467 Konstanz, Konstanz, Germany d Department of Pulmonary Diseases, University Medical Center Groningen, University of Groningen, Hanzeplein 1, 9700 RB, Groningen, The Netherlands Received 18 January 2010; accepted 26 May 2010 Available online 2 July 2010 KEYWORDS Summary Adverse events; Rationale: Patient-reported outcomes provide new insights into the dynamics of asthma Inhaled corticosteroid management. Further to asthma control and quality of life, self-reported side effects of treat- questionnaire; ment can be assessed with the validated Inhaled Corticosteroid Questionnaire (ICQ). ICQ; Objectives: To compare patient-reported side effects between the inhaled corticosteroids Patient-reported ciclesonide and fluticasone propionate. outcomes Methods: Patients with moderate or moderate-to-severe asthma, pre-treated with a constant dose and type of medication, were randomized in three separate studies: 1) once daily cicle- sonide 320 mg(n Z 234) or twice daily fluticasone propionate 200 mg(n Z 240); 2) twice daily ciclesonide 320 mg(n Z 255) or twice daily fluticasone propionate 375 mg(n Z 273); and 3) twice daily ciclesonide 320 mg(n Z 259) or twice daily fluticasone propionate 500 mg (n Z 244).
    [Show full text]
  • 1532 Corticosteroids
    1532 Corticosteroids olone; Ultraderm; Malaysia: Synalar†; Mex.: Cortifung-S; Cortilona; Gr.: Lidex; Ital.: Flu-21†; Topsyn; Mex.: Topsyn; Norw.: Metosyn; Pharmacopoeias. In Br. Cremisona; Farmacorti; Flumicin; Fluomex; Fusalar; Lonason; Synalar; Philipp.: Lidemol; Lidex; Singapore: Lidex†; Spain: Klariderm†; Novoter; BP 2008 (Fluocortolone Hexanoate). A white or creamy-white, Norw.: Synalar; NZ: Synalar; Philipp.: Aplosyn; Cynozet; Synalar; Syntop- Switz.: To p s y m ; To p s y m i n ; UK: Metosyn; USA: Lidex; Vanos. ic; Pol.: Flucinar; Port.: Oto-Synalar N; Synalar; Rus.: Flucinar (Флуцинар); odourless or almost odourless, crystalline powder. It exhibits pol- Multi-ingredient: Austria: Topsym polyvalent; Ger.: Jelliproct; Topsym ymorphism. Practically insoluble in water and in ether; very Sinaflan (Синафлан); S.Afr.: Cortoderm; Fluoderm; Synalar; Singapore: polyvalent; Hung.: Vipsogal†; Israel: Comagis; Mex.: Topsyn-Y; Philipp.: Flunolone-V; Spain: Co Fluocin Fuerte; Cortiespec; Fluocid Forte; Fluoder- Lidex NGN; Spain: Novoter Gentamicina; Switz.: Mycolog N; Topsym slightly soluble in alcohol and in methyl alcohol; slightly soluble mo Fuerte; Flusolgen; Gelidina; Intradermo Corticosteroi†; Synalar; Synalar polyvalent; UK: Vipsogal. in acetone and in dioxan; sparingly soluble in chloroform. Pro- Rectal Simple; Swed.: Synalar; Switz.: Synalar; Thai.: Cervicum; Flu- ciderm†; Flunolone-V; Fulone; Supralan; Synalar; UK: Synalar; USA: Capex; tect from light. Derma-Smoothe/FS; DermOtic; Fluonid; Flurosyn†; Retisert; Synalar; Syn- emol; Venez.: Bratofil; Fluquinol Simple†; Neo-Synalar; Neoflu†. Fluocortin Butyl (BAN, USAN, rINNM) ⊗ Fluocortolone Pivalate (BANM, rINNM) ⊗ Multi-ingredient: Arg.: Adop-Tar†; Tri-Luma; Austria: Myco-Synalar; Procto-Synalar; Synalar N; Belg.: Procto-Synalar; Synalar Bi-Otic; Braz.: Butil éster de la fluocortina; Butylis Fluocortinas; Fluocortine Fluocortolone, pivalate de; Fluocortolone Trimethylacetate; Dermobel†; Dermoxin; Elotin; Fluo-Vaso; Neocinolon; Otauril†; Otocort†; Butyle; SH-K-203.
    [Show full text]
  • New Zealand Data Sheet
    NEW ZEALAND DATA SHEET 1. PRODUCT NAME TRELEGY ELLIPTA 100/62.5/25 fluticasone furoate (100 micrograms)/umeclidinium (as bromide) (62.5 micrograms)/vilanterol (as trifenatate) (25 micrograms), powder for inhalation 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each delivered dose (the dose leaving the mouthpiece of the inhaler) contains 92 micrograms fluticasone furoate, 55 micrograms umeclidinium (equivalent to 65 micrograms umeclidinium [as bromide]) and 22 micrograms vilanterol (as trifenatate). This corresponds to a pre-dispensed dose of 100 micrograms fluticasone furoate, 62.5 micrograms umeclidinium (equivalent to 74.2 micrograms umeclidinium bromide) and 25 micrograms vilanterol (as trifenatate). Excipient with known effect: Each delivered dose contains approximately 25 milligrams of lactose (as monohydrate). For the full list of excipients, see Section 6.1 List of excipients. 3. PHARMACEUTICAL FORM Powder for inhalation. White powder in a light grey inhaler (Ellipta) with a beige mouthpiece cover and a dose counter. 4. CLINICAL PARTICULARS 4.1. Therapeutic indications TRELEGY ELLIPTA is indicated for the maintenance treatment of adults with moderate to severe chronic obstructive pulmonary disease (COPD) who require treatment with a long- acting muscarinic receptor antagonist (LAMA) + long-acting beta2-receptor agonist (LABA) + inhaled corticosteroid (ICS). TRELEGY ELLIPTA should not be used for the initiation of COPD treatment. 4.2. Dose and method of administration Patients can be changed from their existing inhalers to TRELEGY ELLIPTA at the next dose. However it is important that patients do not take other LABA or LAMA or ICS while taking TRELEGY ELLIPTA. A stepwise approach to the management of COPD is recommended, including the cessation of smoking and a pulmonary rehabilitation program.
    [Show full text]
  • Steroid Use in Prednisone Allergy Abby Shuck, Pharmd Candidate
    Steroid Use in Prednisone Allergy Abby Shuck, PharmD candidate 2015 University of Findlay If a patient has an allergy to prednisone and methylprednisolone, what (if any) other corticosteroid can the patient use to avoid an allergic reaction? Corticosteroids very rarely cause allergic reactions in patients that receive them. Since corticosteroids are typically used to treat severe allergic reactions and anaphylaxis, it seems unlikely that these drugs could actually induce an allergic reaction of their own. However, between 0.5-5% of people have reported any sort of reaction to a corticosteroid that they have received.1 Corticosteroids can cause anything from minor skin irritations to full blown anaphylactic shock. Worsening of allergic symptoms during corticosteroid treatment may not always mean that the patient has failed treatment, although it may appear to be so.2,3 There are essentially four classes of corticosteroids: Class A, hydrocortisone-type, Class B, triamcinolone acetonide type, Class C, betamethasone type, and Class D, hydrocortisone-17-butyrate and clobetasone-17-butyrate type. Major* corticosteroids in Class A include cortisone, hydrocortisone, methylprednisolone, prednisolone, and prednisone. Major* corticosteroids in Class B include budesonide, fluocinolone, and triamcinolone. Major* corticosteroids in Class C include beclomethasone and dexamethasone. Finally, major* corticosteroids in Class D include betamethasone, fluticasone, and mometasone.4,5 Class D was later subdivided into Class D1 and D2 depending on the presence or 5,6 absence of a C16 methyl substitution and/or halogenation on C9 of the steroid B-ring. It is often hard to determine what exactly a patient is allergic to if they experience a reaction to a corticosteroid.
    [Show full text]